Benjamin P. Saylor
Saylor is content managing editor for Urology Times.
High-risk prostate cancer: Recommended reading
Our January 2015 installment in the ongoing "New Frontiers in Prostate Cancer" series focuses on the challenges presented by high-risk disease. Here are some recommended articles about the diagnosis and treatment of high-risk prostate cancer.
High-risk prostate cancer: Video resources
Our January 2015 installment in the ongoing "New Frontiers in Prostate Cancer" series focuses on the challenges presented by high-risk disease. Here are some video resources on high-risk prostate cancer.
2014 Year in Review: Men's Health
2014 Year in Review: Men's Health
Urology Times continues its "Year in Review" series with a look at the most-read men's health articles of 2014.
2014 Year in Review: Malpractice
In this installment of our "Year in Review" series, we look at 2014's malpractice headlines, with commentary from Urology Times Editorial Council member John J. Mulcahy, MD, PhD.
2014 Year in Review: Health Policy/Practice Management
Urology Times looks back on the top health policy and practice management stories of 2014, including coverage of the Affordable Care Act and changes in reimbursement.
2014 Year in Review: Prostate Cancer
2014 Year in Review: Prostate Cancer
With emergence of new biomarker and tests, high-profile approvals of treatments for new indication, and the ongoing controversy surrounding PSA screening, prostate cancer remained very much in the urology headlines for 2014. Here are some of the most-read Urology Times articles on the disease.
Robot linked with improved kidney Ca care
Kidney cancer patients were more likely to undergo partial nephrectomy when treated in hospitals that were early adopters of robotic surgery, according to a recent report that one leading expert calls “some of the best evidence to date of a favorable impact of surgical robots in urologic care.”
Low bisphosphonate use seen in men on ADT
Low bisphosphonate use seen in men on ADT
Use of bisphosphonates in men on androgen deprivation therapy (ADT) for prostate cancer remains low despite the fact that the practice is recommended in several guidelines, Canadian researchers say.
Prostate Ca assays show economic, clinical benefits
The Prolaris prostate cancer test could save the health care system $6 billion over 10 years, according to data from one of several new studies examining the economic and clinical benefits of newer biomarker-based prostate cancer assays.
HIV agent may prevent prostate Ca metastases
A receptor involved with HIV therapy also appears to be linked to prostate cancer metastases, according to recent research from Thomas Jefferson University, Philadelphia.

Poll